Epidermolysis bullosa due to drug
ICD-10 L12.31 is a billable code used to indicate a diagnosis of epidermolysis bullosa due to drug.
Epidermolysis bullosa due to drug is a rare dermatological condition characterized by the formation of blisters and erosions on the skin and mucous membranes, triggered by specific medications. Clinically, patients may present with fragile skin that easily blisters in response to minor trauma or friction, leading to painful lesions. The anatomy involved primarily includes the epidermis and dermis, where the structural integrity is compromised due to the adverse drug reaction. Disease progression can vary, with some patients experiencing acute episodes that resolve upon discontinuation of the offending drug, while others may develop chronic skin changes. Diagnostic considerations include a thorough patient history to identify potential drug exposures, clinical examination of skin lesions, and possibly skin biopsy to rule out other forms of epidermolysis bullosa. Laboratory tests may also be warranted to assess for underlying conditions or to confirm the diagnosis. Accurate diagnosis is crucial for effective management and prevention of further complications.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
L12.31 specifically covers cases of epidermolysis bullosa that are directly attributable to adverse drug reactions. This includes conditions where patients develop blistering and skin fragility following the administration of certain medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, or chemotherapeutic agents.
L12.31 should be used when there is clear evidence linking the epidermolysis bullosa to a specific drug exposure. If the condition arises without any known drug association, other codes for non-drug-induced epidermolysis bullosa should be considered.
Documentation for L12.31 should include a detailed patient history highlighting drug exposures, clinical descriptions of skin lesions, treatment responses, and any relevant laboratory findings that support the diagnosis of drug-induced epidermolysis bullosa.
